The stock of Annexon Inc (ANNX) has gone up by 14.37% for the week, with a 8.65% rise in the past month and a 73.31% rise in the past quarter. The volatility ratio for the week is 10.96%, and the volatility levels for the past 30 days are 8.05% for ANNX. The simple moving average for the last 20 days is 11.28% for ANNX’s stock, with a simple moving average of -28.07% for the last 200 days.
Is It Worth Investing in Annexon Inc (NASDAQ: ANNX) Right Now?
ANNX has 36-month beta value of 1.29. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANNX is 95.53M, and currently, short sellers hold a 10.60% ratio of that float. The average trading volume of ANNX on July 09, 2025 was 1.56M shares.
ANNX) stock’s latest price update
The stock price of Annexon Inc (NASDAQ: ANNX) has jumped by 4.24% compared to previous close of $2.71. Despite this, the company has seen a gain of 14.37% in its stock price over the last five trading days. globenewswire.com reported 2025-06-18 that Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors
Analysts’ Opinion of ANNX
Many brokerage firms have already submitted their reports for ANNX stocks, with JP Morgan repeating the rating for ANNX by listing it as a “Overweight.” The predicted price for ANNX in the upcoming period, according to JP Morgan is $11 based on the research report published on March 01, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ANNX reach a price target of $6, previously predicting the price at $4. The rating they have provided for ANNX stocks is “Buy” according to the report published on December 21st, 2023.
Wells Fargo gave a rating of “Overweight” to ANNX, setting the target price at $11 in the report published on October 30th of the previous year.
ANNX Trading at 27.33% from the 50-Day Moving Average
After a stumble in the market that brought ANNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANNX starting from Carson William H., who purchase 4,115 shares at the price of $2.46 back on Jun 30 ’25. After this action, Carson William H. now owns 29,715 shares of Annexon Inc, valued at $10,123 using the latest closing price.
Dananberg Jamie, the CHIEF MEDICAL OFFICER of Annexon Inc, sale 5,521 shares at $2.96 during a trade that took place back on Feb 18 ’25, which means that Dananberg Jamie is holding 33,479 shares at $16,342 based on the most recent closing price.
Stock Fundamentals for ANNX
The total capital return value is set at -0.68. Equity return is now at value -66.13, with -55.14 for asset returns.
Based on Annexon Inc (ANNX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -4.94.
Currently, EBITDA for the company is -134.75 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.99.
Conclusion
To put it simply, Annexon Inc (ANNX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
